CLAIMS

1. Use of an antagonist of the complement system in the manufacture of a medicament for treating a paraproteinemic neuropathy in a subject, the method comprising administering to the subject the antagonist of the complement system, wherein the antagonist inhibits the complement system upstream of complement factor C5.

2. The use of claim 1, wherein the antagonist inhibits the classical complement pathway and/or the lectin complement pathway; and/or

   wherein the paraproteinemic neuropathy is a demyelinating neuropathy; and/or

   wherein the paraproteinemic neuropathy is characterised by the presence of IgM, IgA or IgG immunoglobulins; and/or

   wherein the paraproteinemic neuropathy is characterised by the presence of autoantibodies.

3. The use of claim 1 or claim 2, wherein the paraproteinemic neuropathy is characterised by the presence of autoantibodies against a neural antigen.

4. The use of claim 3, wherein the neural antigen is a ganglioside or myelin-associated glycoprotein (MAG), optionally

   wherein the ganglioside is selected from GM1, GM1b, GM2, GM3, GD1a, GD1b, GD2, GD3, GT1a, GT1b, GT3, and GQ1b, preferably

   wherein the ganglioside is GM1.

5. The use of any one of claims 1-4, wherein the paraproteinemic neuropathy is selected from: multifocal motor neuropathy (MMN), chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome (GBS), Miller Fisher syndrome, acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN), chronic ataxic neuropathy-ophthalmoplegia-IgM paraprotein-cold agglutinins-disialosyl antibodies (CANOMAD) syndrome, distal acquired demyelinating symmetric (DADS) neuropathy, monoclonal gammopathy associated peripheral neuropathy, anti-MAG peripheral neuropathy, and POEMS syndrome.

6. The use of claim 5, wherein the paraproteinemic neuropathy is MMN, CIDP, or GBS, preferably

   wherein the paraproteinemic neuropathy is MMN.

7. The use of any one of claims 1-6, wherein the antagonist inhibits the complement system upstream of complement factor C3, optionally
wherein the antagonist inhibits C1, C1q, C1r or C1s, or
wherein the antagonist inhibits complement factor C2, C2a or C2b, or
wherein the antagonist inhibits complement factor C4, C4a or C4b.

8. The use of any one of claims 1-6, wherein the antagonist inhibits complement factor C3, C3a or C3b.

9. The use of any one of claims 1-8, wherein the antagonist is selected from: an inhibitory RNA species, for example an siRNA or shRNA; a small molecule inhibitor; a biological antagonist, for example an inhibitory peptide or an antibody mimetic such as an affibody, affilin, affitin, adnectin, atrimer, evasin, DARPin, anticalin, avimer, fynomer, versabody or duocalin; or an antibody or antigen-binding fragment thereof.

10. The use of any one of claims 1-9, wherein the antagonist is selected from: compstatin Cp40 (Amyndas); PEG-Cp40 (Amyndas); AMY-101 (Amyndas); AMY-201 (Amyndas); APL-1 and APL-2 (Apellis); Cinryze (Shire); CDX-1135 (Celldex); APT070 Mirococept (MRC); HC3-1496 (InCode); nafamostat (Torii Pharmaceutical); and vaccinia virus complement control protein (VCP).

11. The use of any one of claims 1-8, wherein the antagonist is an antibody or antigen-binding fragment thereof, optionally
wherein the antibody is an IgG antibody, or
wherein the antigen-binding fragment is selected from: an antibody light chain variable domain (VL), an antibody heavy chain variable domain (VH), a single chain antibody (scFv), a $F(ab')_2$ fragment, a Fab fragment, an Fd fragment, an Fv fragment, a one-armed (monovalent) antibody, diabodies, triabodies, tetrabodies, unibodies, domain antibodies and nanobodies.

12. The use of claim 11, wherein the antibody or antigen-binding fragment thereof binds to complement factor C1, C1q, C1s, C2, C2a, C2b, C3, C3a, C3b, C4, C4a or C4b, optionally
wherein the antibody or antigen-binding fragment is selected from: sutimlimab BIV009/TNT009 (Bioverativ); ANX005 (Annexon); mAb H17 (Elusys Therapeutics); and TNT003 (True North).

13. The use of claims 11, wherein the antibody or antigen-binding fragment binds to complement factor C2.

14. The use of claim 13, wherein the antibody or antigen-binding fragment binds to the C2b domain of complement factor C2.

15. The use of claim 14, wherein the antibody or antigen-binding fragment comprises a variable heavy chain domain (VH) and a variable light chain domain (VL) wherein the VH and VL domains comprise the CDR sequences:
    - HCDR3 comprising or consisting of SEQ ID NO: 2;
    - HCDR2 comprising or consisting of SEQ ID NO: 3;
    - HCDR1 comprising or consisting of SEQ ID NO: 4;
    - LCDR3 comprising or consisting of SEQ ID NO: 5;
    - LCDR2 comprising or consisting of SEQ ID NO: 6; and
    - LCDR1 comprising or consisting of SEQ ID NO: 7.

16. The use of claim 15, wherein the antibody or antigen-binding fragment comprises a variable heavy chain (VH) domain and a variable light chain (VL) domain wherein the VH domain comprises or consists of the amino acid sequence of SEQ ID NO: 8 and the VL domain comprises the CDR sequences:
    - LCDR3 comprising or consisting of SEQ ID NO: 5;
    - LCDR2 comprising or consisting of SEQ ID NO: 6; and
    - LCDR1 comprising or consisting of SEQ ID NO: 7.

17. The use of claim 15 or claim 16, wherein the antibody or antigen-binding fragment comprises a VH domain comprising or consisting of the amino acid sequence of SEQ ID NO: 8 or an amino acid sequence having at least 70% identity thereto and a VL domain comprising or consisting of the amino acid sequence of SEQ ID NO: 9 or an amino acid sequence having at least 70% identity thereto.

18. The use of claim 17, wherein the antibody or antigen-binding fragment comprises a VH domain comprising or consisting of the amino acid sequence of SEQ ID NO: 8 and a VL domain comprising or consisting of the amino acid sequence of SEQ ID NO: 9.

19. The use of any one of claims 15-18, wherein the antibody or antigen-binding fragment comprises a human IgG heavy chain constant domain.

20. The use of any one of claims 13-15, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 16 and a light chain comprising the amino acid sequence of SEQ ID NO: 20.

21. The use of any one of claims 1-20, further comprising administering IVIg to the subject, and/or

further comprising administering rituximab to the subject.